{
  "trial_id": "NCT00398112",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, ECOG performance status, creatinine levels, AST levels, ALT levels, bilirubin levels, alkaline phosphatase levels, platelet count, absolute neutrophil count, prior treatments, disease stage, presence of splenomegaly, presence of hepatomegaly, presence of lymphadenopathy, weight loss, fatigue, fever, night sweats, hemoglobin levels, history of cardiac disease, history of pulmonary embolism, history of thyroid abnormalities, history of gastrointestinal disease, history of other malignancies, use of contraception, ability to complete patient diaries, history of cerebrovascular events, blood pressure, history of cardiac arrhythmias, history of heart failure, prior chemotherapy, prior rituximab or alemtuzumab, prior major surgery, prior oral steroids, use of CYP3A4 inhibitors, use of CYP3A4 inducers, use of proarrhythmic agents, use of antiretroviral therapy, use of anticoagulants.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ],
        [
          "creatinine levels",
          "creatinine levels"
        ],
        [
          "AST levels",
          "AST levels"
        ],
        [
          "ALT levels",
          "ALT levels"
        ],
        [
          "bilirubin levels",
          "bilirubin levels"
        ],
        [
          "alkaline phosphatase levels",
          "alkaline phosphatase levels"
        ],
        [
          "platelet count",
          "platelet count"
        ],
        [
          "absolute neutrophil count",
          "absolute neutrophil count"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Fluorescence In Situ Hybridization (FISH) Abnormalities",
        "Rai Stage",
        "ZAP-70 Status",
        "CD38 Status",
        "Immunoglobulin Variable Heavy Chain (IGVH) Mutation Status"
      ],
      "remaining_candidate_features": [
        "prior treatments",
        "disease stage",
        "presence of splenomegaly",
        "presence of hepatomegaly",
        "presence of lymphadenopathy",
        "weight loss",
        "fatigue",
        "fever",
        "night sweats",
        "hemoglobin levels",
        "history of cardiac disease",
        "history of pulmonary embolism",
        "history of thyroid abnormalities",
        "history of gastrointestinal disease",
        "history of other malignancies",
        "use of contraception",
        "ability to complete patient diaries",
        "history of cerebrovascular events",
        "blood pressure",
        "history of cardiac arrhythmias",
        "history of heart failure",
        "prior chemotherapy",
        "prior rituximab or alemtuzumab",
        "prior major surgery",
        "prior oral steroids",
        "use of CYP3A4 inhibitors",
        "use of CYP3A4 inducers",
        "use of proarrhythmic agents",
        "use of antiretroviral therapy",
        "use of anticoagulants"
      ]
    },
    "processed-gen-response": "Age, gender, ECOG performance status, creatinine levels, AST levels, ALT levels, bilirubin levels, alkaline phosphatase levels, platelet count, absolute neutrophil count, prior treatments, disease stage, presence of splenomegaly, presence of hepatomegaly, presence of lymphadenopathy, weight loss, fatigue, fever, night sweats, hemoglobin levels, history of cardiac disease, history of pulmonary embolism, history of thyroid abnormalities, history of gastrointestinal disease, history of other malignancies, use of contraception, ability to complete patient diaries, history of cerebrovascular events, blood pressure, history of cardiac arrhythmias, history of heart failure, prior chemotherapy, prior rituximab or alemtuzumab, prior major surgery, prior oral steroids, use of CYP3A4 inhibitors, use of CYP3A4 inducers, use of proarrhythmic agents, use of antiretroviral therapy, use of anticoagulants."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG performance status, Creatinine, AST, ALT, Bilirubin, Alkaline phosphatase, Platelet count, Absolute neutrophil count, Hemoglobin, Lymphocyte count, Prior chemotherapy, Prior rituximab or alemtuzumab, Prior major surgery, Prior oral steroids, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Fluorescence In Situ Hybridization (FISH) Abnormalities",
        "Rai Stage",
        "ZAP-70 Status",
        "CD38 Status",
        "Immunoglobulin Variable Heavy Chain (IGVH) Mutation Status"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "ECOG performance status",
        "Creatinine",
        "AST",
        "ALT",
        "Bilirubin",
        "Alkaline phosphatase",
        "Platelet count",
        "Absolute neutrophil count",
        "Hemoglobin",
        "Lymphocyte count",
        "Prior chemotherapy",
        "Prior rituximab or alemtuzumab",
        "Prior major surgery",
        "Prior oral steroids"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG performance status, Creatinine, AST, ALT, Bilirubin, Alkaline phosphatase, Platelet count, Absolute neutrophil count, Hemoglobin, Lymphocyte count, Prior chemotherapy, Prior rituximab or alemtuzumab, Prior major surgery, Prior oral steroids"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Chronic Lymphocytic Leukemia (CLL) Duration, Prior Therapy, Rai Stage, Binet Stage, Beta-2 Microglobulin, Lactate Dehydrogenase, Creatinine, Absolute Neutrophil Count, Platelet Count, Hemoglobin.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Rai Stage",
          "Rai Stage"
        ]
      ],
      "remaining_reference_features": [
        "Fluorescence In Situ Hybridization (FISH) Abnormalities",
        "ZAP-70 Status",
        "CD38 Status",
        "Immunoglobulin Variable Heavy Chain (IGVH) Mutation Status"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "ECOG Performance Status",
        "Chronic Lymphocytic Leukemia (CLL) Duration",
        "Prior Therapy",
        "Binet Stage",
        "Beta-2 Microglobulin",
        "Lactate Dehydrogenase",
        "Creatinine",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Hemoglobin"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Chronic Lymphocytic Leukemia (CLL) Duration, Prior Therapy, Rai Stage, Binet Stage, Beta-2 Microglobulin, Lactate Dehydrogenase, Creatinine, Absolute Neutrophil Count, Platelet Count, Hemoglobin."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, weight, height, body mass index (BMI), creatinine, creatinine clearance, AST, ALT, bilirubin, alkaline phosphatase, platelet count, absolute neutrophil count, hemoglobin, prior treatments, time since prior treatment, disease duration, number of prior regimens, presence of B symptoms, lymphocyte count, presence of splenomegaly, hepatomegaly, or lymphadenopathy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ],
        [
          "Fluorescence In Situ Hybridization (FISH) Abnormalities",
          "Fluorescence In Situ Hybridization (FISH) Abnormalities"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Rai Stage",
        "ZAP-70 Status",
        "CD38 Status",
        "Immunoglobulin Variable Heavy Chain (IGVH) Mutation Status"
      ],
      "remaining_candidate_features": [
        "race",
        "weight",
        "height",
        "body mass index (BMI)",
        "creatinine",
        "creatinine clearance",
        "AST",
        "ALT",
        "bilirubin",
        "alkaline phosphatase",
        "platelet count",
        "absolute neutrophil count",
        "hemoglobin",
        "prior treatments",
        "time since prior treatment",
        "disease duration",
        "number of prior regimens",
        "presence of B symptoms",
        "lymphocyte count",
        "presence of splenomegaly",
        "hepatomegaly",
        "or lymphadenopathy."
      ]
    },
    "processed-gen-response": "Age, sex, race, ECOG performance status, weight, height, body mass index (BMI), creatinine, creatinine clearance, AST, ALT, bilirubin, alkaline phosphatase, platelet count, absolute neutrophil count, hemoglobin, prior treatments, time since prior treatment, disease duration, number of prior regimens, presence of B symptoms, lymphocyte count, presence of splenomegaly, hepatomegaly, or lymphadenopathy."
  }
}